Nephrotic Syndrome After Bevacizumab: Case Report and Literature Review

American Journal of Kidney Diseases

Volumn 49, Issue 2, 2007, Pages

  George, Betsy A ^a   Zhou, Xin J ^a   Toto, Robert ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

avastin; Bevacizumab; nephrotic syndrome; proteinuria; vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; CLONIDINE; FUROSEMIDE; GEMCITABINE; MINOXIDIL; OLMESARTAN; QUINAPRIL;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HYPERTENSION; KIDNEY BIOPSY; MALE; NEPHROTIC SYNDROME; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PROTEINURIA;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; MALE; NEPHROTIC SYNDROME; PROTEINURIA;

EID: 33846515280     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.11.024     Document Type: Article

References (18)

1. Midgley R., and Kerr D. Bevacizumab-Current status and future directions. Ann Oncol 16 (2005) 999-1004
2. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
3. Helin K., Honkanen E., Metsaniitty J., and Tornroth T. A case of membranous glomerulonephritis associated with adenocarcinoma of pancreas. Nephrol Dial Transplant 13 (1998) 1049-1050
4. Kanellis J., Fraser S., Katerelos M., and Power D.A. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 278 (2000) F905-F915
5. Shulman K., Rosen S., Tognazzi K., Manseau E.J., and Brown L.F. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 7 (1996) 661-666
6. Wakelin S.J., Marson L., Howie S., Garden J., Lamb J., and Forsythe J. The role of vascular endothelial growth factor in the kidney in health and disease. Nephron Physiol 98 (2004) 73-79
7. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111 (2003) 707-716
8. Boner G., Cox A., Kelly D., et al. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?. Nephrol Dial Transplant 18 (2003) 2293-2299
9. Bortoloso E., Del Prete D., Dalla Vestra M., et al. Quantitative and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol 150 (2004) 799-807
10. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278 (2003) 12605-12608
11. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 17 (2006) 2383-2389
12. Flyvbjerg A., Dagnæs-Hansen F., De Vriese A., Schrijvers B., Tilton R.G., and Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51 (2004) 3090-3094
13. Baelde H.J., Eikmans M., Doran P., Lappin D., Heer E., and Bruijn J. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 43 (2004) 636-650
14. Ostendorf T., Kunter U., Eitner F., et al. VEGF165 mediates glomerular endothelial repair. J Clin Invest 104 (1999) 913-923
15. De Vriese A., Tilton R., Elger M., Stephan C., Kriz W., and Lameire N. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12 (2001) 993-1000
16. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
17. Yang J.C., Haworth L., Sherry R., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
18. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65